2023年1月9日 · Prostate-specific membrane antigen (PSMA)-directed posi-tron emission tomography/computed tomography (PET/CT) is a non-invasive diagnostic technique to image PSMA posi-tive lesions in individuals with prostate cancer. PSMA is a transmembrane protein with an extracellular binding site.

This document provides guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging.

Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands.

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging.

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtain …

2023年3月23日 · Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands. Different scenarios for the clinical use of PSMA-ligand PET/CT are discussed.

2023年1月27日 · Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging.

2017年3月10日 · 68 Ga-PSMA positron emission tomography/computed tomography (PET/CT) is a non-invasive diagnostic technique to image prostate cancer with increased prostate-specific membrane antigen (PSMA, glutamate carboxypeptidase II, EC 3.4.17.21) expression. PSMA is a transmembrane protein primarily present in all prostatic tissues.

PSMA-11 is 50–100 minutes and for 18F-DCFPyL is 60 minutes. A helpful resource for PSMA- 11 PET is provided in the joint European Association of Nuclear Medicine (EANM) and Society

These recommendations will help to improve accuracy, precision, and repeatability of 68 Ga-PSMA PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.